Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
https://doi.org/10.14412/2074-2711-2012-389
Abstract
Dopaminergic stimulation with levodopa, a biological precursor of dopamine precursor, and dopamine receptor agonists (DRA) remains the leading pharmacotherapeutic strategy for Parkinson’s disease (PD). The long-term use of levodopa is associated with the development of characteristic fluctuations in its symptoms and drug-induced dyskinesias so DRA are the drugs of choice and may be used alone and as part of combination therapy in a number of cases of parkinsonism in young patients in particular. Pramipexole (mirapex) is one of the most effective representatives of non-ergoline DRA, which has an extensive evidence base. The paper analyzes the heterodirectional properties of pramipexole in detail and its effect on motor (including tremor) and nonmotor (depression) manifestations of PD and discusses the possible neuroprotective action of the drug. It also separately considers the potential of the new unique 24-hour controlled release formulation: the administration of the drug considerably reduces the dose titration period and enhances patient compliance.
References
1. <div><p>Schapira A.H.V. The management of Parkinson’s disease — what is new? Eur J Neurol 2011;18(Suppl. 1):1-2.</p><p>Шток В.Н., Иванова-Смоленская И.А., Левин О.С. (ред.). Экстрапирамидные расстройства. Рук-во по диагностике и лечению. М.: МЕДпресс-информ, 2002;700 с.</p><p>Poewe W., Antonini A., Zijlmans J.C. et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;7:229-38.</p><p>Иллариошкин С.Н., Федорова Н.В. Современная концепция постоянной дофаминергической стимуляции. В кн.: Болезнь Паркинсона и расстройства движений. Рук-во для врачей. Под ред. С.Н. Иллариошкина, О.С. Левина. М., 2008;154-9.</p><p>Quinn N. Drug treatment of Parkinson’s disease. BMJ 1995;310(Suppl. 9):575-9.</p><p>Kebabian J.W., Calne D.B. Multiple receptor mechanism for dopamine. Nature 1979;227:93-6.</p><p>Rodbell M. Signal transduction: evolution of an idea. In: N.Ringertz (ed). Nobel Lectures, Physiology or Medicine 1991—1995. Singapore: World Scientific, 1997:220-36.</p><p>Le W.D., Jankovic J. Are dopamine receptors agonists neuroprotective in Parkinson’s disease? Drugs Aging 2001;18:389-96.</p><p>Ogawa N., Miyazaki I., Tanaka K. et al. Dopamine D2 receptor mediated antioxidant and neuroprotective effects of ropinirole. Parkinsonism Relat Dis 1999;5:S1-S81.</p><p>Schapira A.H.V., Olanow C.W. Neuroprotection in Parkinson’s disease. Mysteries, Myths and Misconceptions. JAMA 2003;291:358-64. ЛИТЕРАТУРА</p><p>Finotti N., Castagna L., Moretti A. et al. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000;42:287-91.</p><p>Nishibayashi S., Asanuma M., Kohno M. et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J. Neurochem 1996;67:2208-11.</p><p>Rascol O., Slaoui T., Regragui W. et al. Dopamine agonists. In: Koller W.C., Melamed E. (eds). Handbook of Clinical Neuroljgy, Vol. 84: Parkinson’s disease and related disorders. Part II. Elsevier, 2007:73-92.</p><p>Gu M., Iravani M.M., Cooper J.M. et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004;91:1075-81.</p><p>Schapira A.H.V. Progress in neuroprotection in Parkinson’s disease. Eur J Neurol 2008;15(Suppl. 1):5-13.</p><p>Stocchi F. Neuroprotection in Parkinson’s disease: clinical trials. In: Koller W.C., Melamed E. (eds). Handbook of Clinical Neurology, Vol. 84: Parkinson’s disease and related disorders. Part II. Elsevier, 2007:17-29.</p><p>Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. J Clin Neuropharmacol 2000;23:34-44.</p><p>Whone A.L., Watts R.L., Stoessl A.J. et al. REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REALPET study. Ann Neurol 2003;54:93-101.</p><p>LeWitte P.A., Taylor D.C. Protection against Parkinson’s disease progression: clinical experi ence. Neurotherapeutics 2008;5:210-25.</p><p>Molho E.S., Factor S.A., Weiner W.J. et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease. J Neural Transm 1995;45:(Suppl.):225-30.</p><p>Wong K.S., Lu S.-C., Shan D.-E. et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J Neurol Sci 2003;216:81-7.</p><p>Shannon K.M., Bennett J.P., Friedman J.H. Efficacy of pramipexol, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997;49:724-8.</p><p>Федорова Н.В. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. В кн.: Болезнь Паркинсона и расстройства движений. Рук-во для врачей. Под ред. С.Н. Иллариошкина, О.С. Левина. М., 2008;162—70.</p><p>Mizuno Y., Yanagisawa N., Kuno S. et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Dis 2003;18:1149-56.</p><p>Иванова-Смоленская И.А., Маркова Е.Д., Иллариошкин С.Н. Агонисты дофаминовых рецепторов в лечении больных первичным паркинсонизмом молодого возраста. Неврол журн 2002;2:38-41.</p><p>Иллариошкин С.Н., Иванова-Смоленская И.А., Загоровская Т.Б. и др. Семилетний опыт применения Мирапекса у больных с различными формами первичного паркинсонизма. Журн неврол и психиатр 2006;11:26-32.</p><p>Иллариошкин С.Н. Терапия паркинсонизма: возможности и перспективы. Cons Med 2009(прил. Неврология);1:35-40.</p><p>Navan P., Findley L.J., Jeffs J.A.R. et al. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Mov Diso 2003:18:176-80.</p><p>Pogarell O., Gasser T., van Hilten J.J. et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-20.</p><p>Яхно Н.Н., Нодель М.Р. Применение препарата мирапекс при болезни Паркинсона. Методические рекомендации. М., 2000; 28 с.</p><p>Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-8.</p><p>Kunig G., Pogarell O., Moller J.C. et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson s disease. Clin Neuropharmacol 1999;22:301-5.</p><p>Moller J.C., Oertel W.H. Pramipexole in the treatment of advanced Parkinson s disease. Eur J Neurol 2000;7(Suppl. l):21-5.</p><p>Reijinders J.S., Ehrt U., Weber W.E. et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Dis 2007;23:183-9.</p><p>Chaudhuri K.R., Healy D.G., Schapira A.H.V. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-45.</p><p>Barone P., Poewe W., Albrecht S. et al. Pramipexole for the treatment of deprtessive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80.</p><p>Нодель М.Р., Яхно Н.Н. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журн неврол и психиатр 2008;5:32-8.</p><p>Corrigan M.H., Denahan A.Q., Wright C.E. et al. Comparison of pramipexol, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.</p><p>Zarate C.A., Payne J.L., Singh J. et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.</p><p>Diaz-Martinez A., Benassinni O., Ontiveros A. et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998;20:467-76.</p><p>Watanabe S., Yokoyama S., Kubo S. et al. A double-blind controlled study of clinical efficacy of maprotiline and amitriptyline in depres sion. Folia Psychiatr Neurol Jpn 1978;32:1-31.</p><p>Ishikawa A., Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996;47:160-6.</p><p>Brotchie J.M., Lee J., Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-91.</p><p>Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(Suppl. 2):II43-II50.</p><p>Rascol O. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Eur J Neurol 2011;18(Suppl. 1):3—10.</p><p>Hauser R.A., Schapira A.H., Rascol O. et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Dis 2010;25:2542-9.</p><p>Schapira A.H., Barone P., Hauser R.A. et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease. Movement Disorder Society 13th International Congress. Paris, 2009: Poster We-199.</p><p>Rascol O., Barone P., Hauser R.A. et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov Dis 2010;25:2326-32.</p></div><br />
Review
For citations:
Illarioshkin S.N. Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):78-83. (In Russ.) https://doi.org/10.14412/2074-2711-2012-389
Views: 823
Email this article 